Stoke Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

STOK$27.21-1.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated statements of stockholders’ equity

Common Stock · Additionalpaid-in · Accumulated Other Comprehensive · Accumulated · Total
	Shares	Amount	capital	Gain (Loss)	deficit	Stockholders’equity
Balance as of December 31, 2021	36,902,499	$4	$414,024	$(168)	$(196,083)	$217,777
Unrealized loss on marketable securities	—	—	—	(1,007)	—	(1,007)
Stock-based compensation	—	—	22,854	—	—	22,854
Issuance of common stock upon exercise of stock options	269,288	—	494	—	—	494
Issuance of common stock related to employee stock purchase plan	44,002	—	570	—	—	570
Shares sold as part of controlled equity offering sales agreement	2,223,786	—	45,228	—	—	45,228
Net loss	—	—	—	—	(101,067)	(101,067)
Balance as of December 31, 2022	39,439,575	$4	$483,170	$(1,175)	$(297,150)	$184,849
Unrealized gain on marketable securities	—	—	—	1,151	—	1,151
Stock-based compensation	—	—	25,257	—	—	25,257
Issuance of common stock upon exercise of stock options	148,211	—	371	—	—	371
Issuance of common stock related to employee stock purchase plan	71,471	—	555	—	—	555
Shares sold as part of controlled equity offering sales agreement	6,258,976	1	52,080	—	—	52,081
Net loss	—	—	—	—	(104,699)	(104,699)
Balance as of December 31, 2023	45,918,233	$5	$561,433	$(24)	$(401,849)	$159,565

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.